GlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the FDA raised problems with a challenger. Reuters reports today that ...
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback